Clinical Trials Browser

Phase 3 × Peritoneal Neoplasms × nintedanib × Clear all

NCT01015118 2017-12-07

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Phase 3 Completed

1,366 enrolled 17 charts

Ovarian Neoplasms, Peritoneal Neoplasms